A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).

Key facts

Study ID

NCT03595059

Run by

AbbVie

People needed

168

Starts

2018-07-13

Expected to finish

2025-09-12

Last updated by the study team

2025-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has a histologic or cytologic diagnosis of a malignant solid tumor.
• Participants enrolled in Part 2a (monotherapy, dose expansion) must have small cell lung cancer (SCLC) diagnosis; participants enrolled to Part 2b (combination therapy, dose expansion) must have either NSCLC or HR-positive/HER2-negative breast cancer.
• Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
• Failure of at least 1 prior systemic chemotherapy including all available standard therapies for participants in the dose-escalation phase (Parts 1a and 1b) including the safety lead-in phase (Japan only).
• All participants with breast cancer for subjects in the dose-expansion phase (Part 2b only) must have the following:
• Locally advanced or metastatic HR-positive/HER2-negative breast cancer after failing cyclin-dependent kinase (CDK)4/6 inhibitor-based therapy.
• HR-positivity and HER-2-negativity should be confirmed based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria.
• All participants with non-small cell lung cancer (NSCLC) for participants in the dose-expansion phase (Part 2b only) must have R/R NSCLC after at least 1 line of therapy. Participants with activating mutations in EGFR, ALK/ROS1, BRAF genes, or with positive expression of PD-L1 must have been treated with the appropriate targeted therapies.
• All participants with SCLC in the dose-expansion phase (Part 2a only) must have R/R SCLC from at least 1 line of therapy which includes a platinum-based therapy with or without an anti-PD-1/PD-L1 therapy.
• All participants with either breast cancer or NSCLC must have the following if exposed to prior taxane-based therapy:
• No history of taxane allergy (Part 1b and Part 2b only).
• Disease that has relapsed or progressed at least 2 months after most recent exposure to any taxane-based therapy.
• Available tumor tissue suitable for immunohistochemistry testing.
• Adequate kidney, liver, and hematologic laboratory values as described in the protocol.

You may not qualify if…

• Untreated brain or meningeal metastases (participants with a history of metastases may be eligible based on details described in the protocol).
• Grade 2 or higher peripheral neuropathy (only applies to participants who would receive taxane therapy).
• Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.
• Known active infection of hepatitis B, hepatitis C, or human immunodeficiency virus with exceptions as described in the protocol.
• Recent history (within 6 months) of congestive heart failure (defined in the protocol), ischemic cardiovascular event, cardiac arrhythmia requiring pharmacological or surgical intervention, pericardial effusion, or pericarditis.
• Any history of hypersensitivity to any ingredients of ABBV-155 will be excluded. For combination therapy only (Parts 1b and 2b), no history of serious allergic reaction to any taxane or any ingredients used in taxane formulation (e.g., cremaphor).

Where it is running

• University of Alabama at Birmingham - Main /ID# 214024 — Birmingham, Alabama, United States
• Highlands Oncology Group, PA /ID# 201568 — Springdale, Arkansas, United States
• UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 206105 — Orange, California, United States
• Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 204267 — West Hollywood, California, United States
• Univ of Colorado Cancer Center /ID# 208365 — Aurora, Colorado, United States
• Yale University, Yale Cancer Center /ID# 201542 — New Haven, Connecticut, United States
• AdventHealth Orlando /ID# 227242 — Orlando, Florida, United States
• Northwestern University Feinberg School of Medicine /ID# 201563 — Chicago, Illinois, United States
• Duplicate_Johns Hopkins Bayview Med Cnt /ID# 215095 — Baltimore, Maryland, United States
• Johns Hopkins Hospital /ID# 201320 — Baltimore, Maryland, United States
• Dana-Farber Cancer Institute /ID# 201564 — Boston, Massachusetts, United States
• Duplicate_Henry Ford Hospital /ID# 226852 — Detroit, Michigan, United States
• Northwell Health - Marcus Ave /ID# 204376 — New Hyde Park, New York, United States
• Carolina BioOncology Institute /ID# 201577 — Huntersville, North Carolina, United States
• Univ Hosp Cleveland /ID# 201567 — Cleveland, Ohio, United States
• University of Oklahoma, Stephenson Cancer Center /ID# 206820 — Oklahoma City, Oklahoma, United States
• Lifespan Cancer Institute at Rhode Island Hospital /ID# 204256 — Providence, Rhode Island, United States
• Vanderbilt Ingram Cancer Center /ID# 201575 — Nashville, Tennessee, United States
• Mary Crowley Cancer Research /ID# 214168 — Dallas, Texas, United States
• MD Anderson Cancer Center /ID# 201558 — Houston, Texas, United States
• NEXT Oncology /ID# 204893 — San Antonio, Texas, United States
• Peter MacCallum Cancer Center /ID# 241676 — Melbourne, New South Wales, Australia
• Duplicate_Cross Cancer Institute /ID# 213838 — Edmonton, Alberta, Canada
• University Health Network_Princess Margaret Cancer Centre /ID# 204539 — Toronto, Ontario, Canada
• The Chaim Sheba Medical Center /ID# 230812 — Ramat Gan, Tel Aviv, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.